Samchundang Pharmaceutical hit the upper price limit on the 20th before plunging to the lower limit on the 21st. The stock experienced a 60% swing over the two trading days. The initial surge followed the company's announcement of receiving a Pre-ANDA response from the U.S. Food and Drug Administration (FDA) for its oral semaglutide generic drug development. However, market sentiment reversed sharply on the 21st as investors reassessed the regulatory significance of the Pre-ANDA stage, which represents a pre-consultation phase rather than formal approval application or review commencement. The stock closed at 167,500 won on the 21st after opening at 251,500 won, erasing all gains from the previous session and falling below the 16th closing price of 184,100 won. This volatility in Korean Stocks resulted in approximately 1.677 trillion won in market capitalization evaporation within a single trading day, dropping from roughly 5.6 trillion won to 3.9 trillion won.
Samchundang Pharmaceutical Closes at Lower Price Limit on 21st
According to the Korea Exchange on the 21st, Samchundang Pharmaceutical fell 29.92% (71,500 won) from the previous trading day to reach 167,500 won during the session, hitting the lower price limit. The stock opened at 251,500 won on the 21st and climbed to an intraday high of 254,000 won before selling pressure drove prices downward. The difference between the intraday high and low reached 86,500 won. Market capitalization declined from approximately 5.6 trillion won to 3.9 trillion won, representing a loss of roughly 1.677 trillion won in a single day.
Stock Surges to Upper Limit on 20th After FDA Pre-ANDA Response Announcement
On the 20th, Samchundang Pharmaceutical closed at 239,000 won, up 29.82% from the previous trading day. Buying interest surged following the company's announcement that it received a Pre-ANDA response from the FDA for the development of an oral semaglutide generic drug. Pre-ANDA is a pre-consultation procedure with the FDA regarding development strategy and testing methods. The 21st lower limit close erased all gains from the 20th session and pushed the stock below the 16th closing price of 184,100 won.
Pre-ANDA Represents Pre-Consultation Stage Not Formal Approval
The sharp price decline on the 21st reflected the market's delayed reassessment of the Pre-ANDA response's meaning. Pre-ANDA is a stage where the FDA and the company pre-consult on development strategy and testing methods. It does not signify that formal approval application or review has commenced. Development methods and whether additional clinical trials can be waived remain unconfirmed. Samchundang Pharmaceutical stated that the FDA response reduced considerable regulatory uncertainty in the development pathway. However, the company did not disclose the original response letter, citing protection of core technology and business strategy, leaving market doubts unresolved.
FAQ
What caused Samchundang Pharmaceutical stock to swing 60% over two days?
The stock hit the upper price limit on the 20th after the company announced receiving a Pre-ANDA response from the FDA for oral semaglutide generic drug development. On the 21st, the stock fell to the lower price limit as investors reassessed the Pre-ANDA stage's regulatory meaning, recognizing it as a pre-consultation phase rather than formal approval application or review commencement.
How much market capitalization did Samchundang Pharmaceutical lose on the 21st?
Samchundang Pharmaceutical's market capitalization fell from approximately 5.6 trillion won to 3.9 trillion won on the 21st, resulting in approximately 1.677 trillion won in evaporation within a single trading day. The stock closed at 167,500 won after opening at 251,500 won, with an intraday high-low spread of 86,500 won.
What is the Pre-ANDA stage in FDA drug approval?
Pre-ANDA is a pre-consultation stage where the FDA and a company discuss development strategy and testing methods before formal approval application. It does not signify that formal approval application or review has begun. Development methods and additional clinical trial waiver status remain unconfirmed at this stage.
